Key result
In vitro PAD1-4 profiling identifies ~30,000 citrullination sites, revealing broad PAD1-2 and targeted PAD3-4 specificities.
Why the study?
Protein arginine deiminases 1 to 4 are catalytically active with distinct tissue-specificities, yet isozyme-specific substrate recognition remains poorly defined.
Provides a comprehensive in vitro atlas of maximal substrate capacity for PAD isozymes, defining specific motifs and molecular determinants to guide selective inhibitors.
Does not change clinical practice; extends in vitro atlas of PAD motifs to guide selective inhibitor development.
Protein arginine deiminases (PADs) convert arginine to citrulline, altering protein structure. Of the five human isozymes, PAD1–4 are catalytically active with distinct tissue-specificities, yet isozyme-specific substrate recognition remains poorly defined. Here, we perform in vitro lysate-based substrate profiling of PAD1–4 via mass spectrometry across human H4 and HeLa cell lines, identifying ~30,000 citrullination sites across ~5,500 proteins. Only 14% of sites are shared among all, reflecting distinct sequence preferences: PAD1–2 show broad specificity, whereas PAD3–4 favor arginines flanked by acidic or glycine residues. These preferences persist over 10 min–16 h, indicating sequence context rather than temporal dynamics drives specificity. Mutation analysis of eleven PAD4 variants reveal Q346, G403, R639, and H640 as key determinants distinguishing substrate recognition from that of PAD2. This work provides a comprehensive in vitro atlas of maximal substrate capacity, defining isozyme-specific motifs and molecular determinants to guide selective inhibitors and probes for citrullination mechanisms in health and disease.
No takes yet. Share an insight, caveat, or question.
Laposchan et al. (2026) studied this question. In vitro lysate-based substrate profiling of PAD1-4 was evaluated on Identification of citrullination sites and isozyme-specific substrate recognition. In vitro lysate-based profiling of PAD1-4 identified ~30,000 citrullination sites, revealing that PAD1-2 have broad specificity while PAD3-4 favor arginines flanked by acidic or glycine residues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: